US Patent

US8022228 — Crystal form of asenapine maleate

Composition of Matter · Assigned to Organon NV · Expires 2026-04-06 · 0y expired

Vulnerability score 12/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects an orthorhombic crystal form of asenapine maleate, a method for preparing it, and pharmaceutical compositions containing this crystal form.

USPTO Abstract

The invention relates to an orthorhombic crystal form of compound trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole(Z)-2-butenedioate, to methods for the preparation of this crystal form and to pharmaceutical compositions comprising an orthorhombic crystal form.

Drugs covered by this patent

Patent Metadata

Patent number
US8022228
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-04-06
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Organon NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.